



IASLC



11th European Regional Conference on Thoracic Oncology: Where We Are Now?



An initiative of the Chinese – European Alliance of Oncology in collaboration with National Cancer Institute (Lithuania), Vilnius University, Lithuanian Society of Oncology, Medical University of Białystok, Euroregional Medical Centre for Research and Education, Mannheim University, Lithuanian Society of Pulmonology and IASLC

**13-15th of June 2019,
Vilnius, Lithuania**

PRELIMINARY SCIENTIFIC PROGRAMME

Thursday, 13 June 2019

17:00-18:00	Young Investigators Session Chairs: M.Moniuzsko, S.Cicenas	
18:00-18:30	How to prepare a scientific poster by a young oncologist	R.Krasteva Sofia, Bulgaria
	Discussion	

19:00-22:30 Faculty dinner

Friday, 14 June 2019

07:00-08:00	Registration
08:00-08:30	Welcome address Moderation: Ch. Manegold, J. Niklinski, S.Cicenas 1. Lithuanian Minister of Health (SAM) 2. Rector of Vilnius University (VU Rektorius) 3. Dean of the Faculty of Medicine (MF dekanas) 4. Director of National Cancer Institute (NVI direktorius) 5. President of Cancer Patients Support Association (POLA prezidentas) Music introduction

08:30-09:15	Epidemiology/Lung Cancer Screening/Tobacco Control Chairs: Xin Wang, Lothar R.Pilz	
08:30-08:45	Key statistics in lung cancer epidemiology	Lothar R.Pilz Mannheim, Germany
08:45-09:00	Lung Cancer Screening	Maria-Katharina Ganden/V.Gedvilaitė Mannheim, Germany/Vln LT
09:00-09:15	Smoking prevention / Tobacco Control in China	Huijuan Wang Henan, China
9:15-10:30	Pathology/ Molecular Diagnostics Chairs: K.Suziedelis, R.M.Mroz,	
9:15-9:30	Imaging to Address Tumor Heterogeneity	W. Voigt Erlangen, Germany
9:30-9:45	Pathology: New generation sequencing (NGS) in today's diagnostic algorithm	M.Papotti Torino, Italy
9:45-10:00	Gene Editing in Lung Cancer	R.M.Mroz Bialystok, Poland
10:00-10:15	Current algorithm for molecular testing in NSCLC in China	Xiaoxia Chen Shanghai, China
10:15-10:30	Molecular Tools for Lung Cancer Diagnosis	K.Suziedelis Vilnius, Lithuania
10:30-11:15	Invited Speaker Chairs:	
10:30-11:15	Invited Speaker	Invited Speaker (AstraZeneca)
11:15-12:00	Invited Speaker Chairs:	
11:15-12:00	New PD-L1 inhibitors in non-small cell lung cancer	J.Bublevič Vilnius, Lithuania (Roche)

12:00-12:15 **Coffee break**

12:15-13:15	Surgery for Lung Cancer Chairs: M. Kozlowski, T.Grodzki, M.Zielinski	
12:15-12:30	Video Assisted Thoracic Surgery (VATS) in Lung Cancer	M.Kozlowski Bialystok, Poland
12:30-12:45	IASLC view on Thoracic Surgeon	T.Grodzki Szczecin, Poland
12:45-13:00	VAMLA in Staging of Lung Cancer	M.Zielinski Zakopane, Poland

13:00-14:00 Lunch

14:00-14:45	Medical Management of Lung Cancer Part 1 Chairs: R.Pirker, E.Danila	
14:00-14:15	Treatment of Early stage NSCLC	S.Zaremba Vilnius, Lithuania
14:15-14:30	The potential role of neo-adjuvant therapy in NSCLC in China	To be determined China
14:30-14:45	Adjuvant Treatment	R.Pirker Vienna, Austria
14:45-15:30	Invited Speaker Chairs: S.Cicenas	
14:45-15:30	The Importance of Immunotherapy in Treatment-naive Metastatic NSCLC: Optimizing Survival and Response	M. Hochmair Vienna, Austria MSD (Merk)
15:30-16:45	Medical Management of Lung Cancer Part 2 Chairs: R.M.Mroz, R.Zablockis	
15:30-15:45	Chemotherapy first and second-line	L.Norkienė Vilnius, Lithuania
15:45-16:00	Radiotherapy and chemoradiation	A.Wrona/R.Steponavičienė Gdansk, Poland/Lithuania
16:00-16:15	Combining Radiotherapy and targeted therapy in NSCLC	Zhengfei Zhu Shanghai, China
16:15-16:30	Treatment algorithm in mutant NSCLC in China	Tianqing Chu Shanghai, China

16:30-17:15	Invited Speaker Chairs:	
16:30-17:15	Invited Speaker	L.Norkienė Vilnius, Lithuania Bristol Myers (Amicus)
17:15-18:00	Invited Speaker Chairs:	
17:15-18:00	Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)	Invited speaker (Boehringer-Ingelheim)
18:00-18:30	Coffee break	
18:30-19:30	Immuno-oncology of Lung Cancer Chairs: Ch. Manegold, L.Crino	
18:30-18:45	The value of the biomarker PD-L1 IHC in predicting checkpoint inhibitors efficiency in NSCLC: remarks from a medical statistician	Lothar R.Pilz Mannheim, Germany
18:45-19:00	Medical anti-angiogenesis in lung cancer in times of targeted therapy and checkpoint inhibitors	Ch.Manegold Mannheim, Germany
19:00-19:15	Checkpoint inhibitors for early and locally advanced NSCLC	S.Baka Athens, Greece
19:15-19:30	How to optimal sequence ALK inhibitors in NSCLC	L.Crino Perugia, Italy
19:30-19:45	Treatment of Pleural Mesothelioma Chairs: R.Zablockis	
19:30-19:45	Novel approaches in the medical treatment of malignant pleural mesothelioma (MPM)	Jan van Meerbeek Rotterdam, Netherlands

19:45

Dinner

Saturday, 15 June 2019**09:00-9:45 Selected case reports part 1**
Chairs: **S.Cicenas, M.V. Burmistrov**

9:00-9:15	Features of hereditary mutations in the DNA repair system in patients with esophageal cancer	M.V.Burmistrov (M.G.Gordiev, M.V.Aglullina, R.F. Yenikeev) Kazan, Russia
9:15-9:30	A case of complex cancer treatment of intrathoracic esophagus after endoscopic tumor perforation and pleural empyema	M.V.Aglullina (M.V.Burmistrov, V.Yu. Matveev, O.V.Morov) Kazan, Russia
9:30-9:45	Laryngopharyngoesophagectomy as a component of combined treatment of locally advanced cancer of the cervical esophagus and laryngopharynx.	A.Rudyk E.Sigal, M.V.Burmistrov, T.Sharapov, R.Hamidullin Kazan, Russia

9:45-10:00 Coffee break**10:00-10:45 Selected case reports part 2**
Chairs: **S.Cicenas, M.V. Burmistrov**

10:00-10:15	A Case Report	V.Gedvilaitė Vilnius, Lithuania
10:15-10:30	A Case Report	A.Cesas KUL Klaipeda, Lithuania
10:30-10:45	A Case Report	A.Cesas KUL Klaipeda, Lithuania

10:45 Closing remarks
Moderation: **S. Cicenass, J. Niklinski, Ch. Manegold**